Clinical Trial

PhaseV Appoints Head of Business Development Amid Growing Demand for its ML-Powered Clinical Trial Optimization Platform

Former PathAI Business Development Senior Director Hamza Sheikh Joins Company to Support Growing Customer Base and Strengthen Global Impact BOSTON,…

1 year ago

InsightRX to Present Abstracts On Vancomycin Pharmacokinetic Model Performance, MIPD Protocols at ACoP15 Conference

SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- InsightRX – the leader in Bayesian model-informed precision dosing (MIPD) software – today announced it…

1 year ago

PIECES TECHNOLOGIES AWARDED $2M FROM NATIONAL CANCER INSTITUTE, PART OF THE NATIONAL INSTITUTES OF HEALTH, TO ADVANCE USE OF CONVERSATIONAL AI TO IMPROVE THE CARE OF CANCER PATIENTS

Pieces will deploy new conversational AI at MetroHealth that will interact directly with cancer patients and leverage pioneering human oversight…

1 year ago

Cellev8 and Zyppah Team Up to Give Snoring a Rest

Cellev8 and Zyppah Announce Collaborative Sales Agreement Targeting 90 Million Snoring Americans.WELLINGTON, FL / ACCESSWIRE / October 29, 2024 /…

1 year ago

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today…

1 year ago

Dr. Falk Pharma Acquires Kynos Therapeutics, Adding Acute Pancreatitis as a Therapeutic Focus and Further Strengthening Its Development Portfolio

FREIBURG, GERMANY / ACCESSWIRE / October 29, 2024 / Today, Dr. Falk Pharma GmbH announces the successful acquisition of Kynos…

1 year ago

Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia

TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical…

1 year ago

NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15,…

1 year ago